Health Care • Medicinal Chemicals and Botanical Products
$14.34 ▼ -0.28
(-1.91%)
MKT CAP: $265.0M • VOL: 129.6K
52W L $13 52W H $24
USNA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-01-03 | FY 2024
FILED 2024-12-28 | FY 2023
FILED 2023-12-30 |
|---|---|---|---|
| Revenue (Total Sales) | $925.3M | $854.5M | $921.0M |
| YoY Revenue Growth % | +8.3% | -7.2% | — |
| Gross Profit | $724.4M | $693.3M | — |
| Gross Margin % | 78.3% | 81.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $37.4M | $66.3M | $93.1M |
| Operating Margin % | 4.0% | 7.8% | 10.1% |
| Net Income (GAAP) | $10.8M | $42.0M | $63.8M |
| EBITDA (Normalized) | $48.5M | $74.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $22.3M | $61.0M | $70.6M |
| Capital Expenditures (CapEx) | $13.8M | $10.1M | — |
| Free Cash Flow (FCF) | $8.5M | $50.9M | $70.6M |
| FCF Margin % | 0.9% | 6.0% | 7.7% |
| Return on Invested Capital (ROIC %) | 7.9% | 15.0% | — |
| Cash & Short-Term Equivalents | $158.4M | $181.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $533.1M | $532.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR USNA.